Literature DB >> 29076783

Systematic histopathological analysis of different 5-aminolevulinic acid-induced fluorescence levels in newly diagnosed glioblastomas.

Barbara Kiesel1,2,3, Mario Mischkulnig1, Adelheid Woehrer2,3, Mauricio Martinez-Moreno1, Matthias Millesi1,3, Ammar Mallouhi4,3, Thomas Czech1,3, Matthias Preusser5,3, Johannes A Hainfellner2,3, Stefan Wolfsberger1,3, Engelbert Knosp1,3, Georg Widhalm1,3.   

Abstract

OBJECTIVE Glioblastoma (GBM) is characterized by distinct intratumoral histopathological heterogeneity with regard to variable tumor morphology, cell proliferation, and microvascularity. Maximum resection of a GBM results in an improved prognosis and thus represents the aim of surgery in the majority of cases. Fluorescence-guided surgery using 5-aminolevulinic acid (5-ALA) is currently widely applied for improved intraoperative tumor visualization in patients with a GBM. Three intratumoral fluorescence levels (i.e., strong, vague, or no fluorescence) can usually be distinguished during surgery. So far, however, their exact histopathological correlates and their surgical relevance have not been clarified sufficiently. Thus, the aim of this study was to systematically analyze tissue samples from newly diagnosed GBMs with different fluorescence levels according to relevant histopathological parameters. METHODS This prospective study recruited patients who underwent 5-ALA fluorescence-guided resection of a newly diagnosed radiologically suspected GBM. Each patient received 5-ALA approximately 3 hours before surgery, and a modified neurosurgical microscope was applied for intraoperative visualization of 5-ALA-induced fluorescence. During surgery, tissue samples with strong, vague, or no fluorescence were collected. For each sample, the presence of tumor tissue, quality of tissue (compact, infiltrative, or no tumor), histopathological criteria of malignancy (cell density, nuclear pleomorphism, mitotic activity, and presence of microvascular proliferation/necrosis), proliferation rate (MIB-1 labeling index [LI]), and microvessel density (using CD34 staining) were investigated. RESULTS Altogether, 77 patients with a newly diagnosed, histopathologically confirmed GBM were included, and 131 samples with strong fluorescence, 69 samples with vague fluorescence, and 67 samples with no fluorescence were collected. Tumor tissue was detected in all 131 (100%) of the samples with strong fluorescence and in 65 (94%) of the 69 samples with vague fluorescence. However, mostly infiltrative tumor tissue was still found in 33 (49%) of 67 samples despite their lack of fluorescence. Strong fluorescence corresponded to compact tumors in 109 (83%) of 131 samples, whereas vague fluorescence was consistent with infiltrative tumors in 44 (64%) of 69 samples. In terms of the histopathological criteria of malignancy, a significant positive correlation of all analyzed parameters comprising cell density, nuclear pleomorphism, mitotic activity, microvascular proliferation, and necrosis with the 3 fluorescence levels was observed (p < 0.001). Furthermore, the proliferation rate significantly and positively correlated with strong (MIB-1 LI 28.3%), vague (MIB-1 LI 16.7%), and no (MIB-1 LI 8.8%) fluorescence (p < 0.001). Last, a significantly higher microvessel density was detected in samples with strong fluorescence (CD34 125.5 vessels/0.25 mm2) than in those with vague (CD34 82.8 vessels/0.25 mm2) or no (CD34 68.6 vessels/0.25 mm2) fluorescence (p < 0.001). CONCLUSIONS Strong and vague 5-ALA-induced fluorescence enables visualization of intratumoral areas with specific histopathological features and thus supports neurosurgeons in improving the extent of resection in patients with a newly diagnosed GBM. Despite the lack of fluorescence, tumor tissue was still observed in approximately half of the cases. To overcome this current limitation, the promising approach of complementary spectroscopic measurement of fluorescence should be investigated further.

Entities:  

Keywords:  5-ALA; 5-ALA = 5-aminolevulinic acid; CE = contrast enhancement; DTI = diffusion tensor imaging; GBM = glioblastoma; IDH1 = isocitrate dehydrogenase 1; LI = labeling index; NPV = negative predictive value; PPV = positive predictive value; PpIX = protoporphyrin IX; fMRI = functional MRI; fluorescence; glioblastoma; histopathology; microvessel density; oncology; proliferation rate

Mesh:

Substances:

Year:  2017        PMID: 29076783     DOI: 10.3171/2017.4.JNS162991

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  11 in total

1.  Comparison of Panitumumab-IRDye800CW and 5-Aminolevulinic Acid to Provide Optical Contrast in a Model of Glioblastoma Multiforme.

Authors:  Tiara S Napier; Neha Udayakumar; Aditi H Jani; Yolanda E Hartman; Hailey A Houson; Lindsay Moore; Hope M Amm; Nynke S van den Berg; Anna G Sorace; Jason M Warram
Journal:  Mol Cancer Ther       Date:  2020-06-30       Impact factor: 6.261

Review 2.  Fluorescence Guidance and Intraoperative Adjuvants to Maximize Extent of Resection.

Authors:  Cordelia Orillac; Walter Stummer; Daniel A Orringer
Journal:  Neurosurgery       Date:  2021-10-13       Impact factor: 4.654

3.  Widefield fluorescence lifetime imaging of protoporphyrin IX for fluorescence-guided neurosurgery: An ex vivo feasibility study.

Authors:  Mikael T Erkkilä; Bianca Bauer; Nancy Hecker-Denschlag; Maria J Madera Medina; Rainer A Leitgeb; Angelika Unterhuber; Johanna Gesperger; Thomas Roetzer; Christoph Hauger; Wolfgang Drexler; Georg Widhalm; Marco Andreana
Journal:  J Biophotonics       Date:  2019-02-20       Impact factor: 3.207

4.  TCGA mRNA Expression Analysis of the Heme Biosynthesis Pathway in Diffusely Infiltrating Gliomas: A Comparison of Typically 5-ALA Fluorescent and Non-Fluorescent Gliomas.

Authors:  Mario Mischkulnig; Barbara Kiesel; Daniela Lötsch; Thomas Roetzer; Martin Borkovec; Lisa I Wadiura; Petra A Mercea; Florian J Jaklin; Shawn Hervey-Jumper; Karl Roessler; Mitchel S Berger; Georg Widhalm; Friedrich Erhart
Journal:  Cancers (Basel)       Date:  2020-07-24       Impact factor: 6.639

5.  High Diagnostic Accuracy of Visible 5-ALA Fluorescence in Meningioma Surgery According to Histopathological Analysis of Tumor Bulk and Peritumoral Tissue.

Authors:  Lisa I Wadiura; Matthias Millesi; Jessica Makolli; Jonathan Wais; Barbara Kiesel; Mario Mischkulnig; Petra A Mercea; Thomas Roetzer; Engelbert Knosp; Karl Rössler; Georg Widhalm
Journal:  Lasers Surg Med       Date:  2020-07-01       Impact factor: 4.025

Review 6.  Effect of 5-Aminolevulinic Acid and Sodium Fluorescein on the Extent of Resection in High-Grade Gliomas and Brain Metastasis.

Authors:  Lasse Cramer Ahrens; Mathias Green Krabbenhøft; Rasmus Würgler Hansen; Nikola Mikic; Christian Bonde Pedersen; Frantz Rom Poulsen; Anders Rosendal Korshoej
Journal:  Cancers (Basel)       Date:  2022-01-26       Impact factor: 6.639

7.  Efficacy, Outcome, and Safety of Elderly Patients with Glioblastoma in the 5-ALA Era: Single Center Experience of More Than 10 Years.

Authors:  Barbara Kiesel; Lisa I Wadiura; Mario Mischkulnig; Jessica Makolli; Veronika Sperl; Martin Borkovec; Julia Freund; Alexandra Lang; Matthias Millesi; Anna S Berghoff; Julia Furtner; Adelheid Woehrer; Georg Widhalm
Journal:  Cancers (Basel)       Date:  2021-12-04       Impact factor: 6.639

8.  5-Aminolevulinic Acid False-Positive Rates in Newly Diagnosed and Recurrent Glioblastoma: Do Pseudoprogression and Radionecrosis Play a Role? A Meta-Analysis.

Authors:  Luca Ricciardi; Carmelo Lucio Sturiale; Alba Scerrati; Vito Stifano; Teresa Somma; Tamara Ius; Sokol Trungu; Michele Acqui; Antonino Raco; Massimo Miscusi; Giuseppe Maria Della Pepa
Journal:  Front Oncol       Date:  2022-02-17       Impact factor: 6.244

9.  High Interobserver Agreement in the Subjective Classification of 5-Aminolevulinic Acid Fluorescence Levels in Newly Diagnosed Glioblastomas.

Authors:  Mario Mischkulnig; Barbara Kiesel; Martin Borkovec; Lisa I Wadiura; Dimitri Benner; Arthur Hosmann; Shawn Hervey-Jumper; Engelbert Knosp; Karl Roessler; Mitchel S Berger; Georg Widhalm
Journal:  Lasers Surg Med       Date:  2020-03-08       Impact factor: 4.025

10.  5-ALA Fluorescence Is a Powerful Prognostic Marker during Surgery of Low-Grade Gliomas (WHO Grade II)-Experience at Two Specialized Centers.

Authors:  Arthur Hosmann; Matthias Millesi; Lisa I Wadiura; Barbara Kiesel; Petra A Mercea; Mario Mischkulnig; Martin Borkovec; Julia Furtner; Thomas Roetzer; Stefan Wolfsberger; Joanna J Phillips; Anna S Berghoff; Shawn Hervey-Jumper; Mitchel S Berger; Georg Widhalm
Journal:  Cancers (Basel)       Date:  2021-05-21       Impact factor: 6.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.